Neutrophil-to-lymphocyte ratio as a prognostic marker for anaplastic thyroid cancer treated with lenvatinib

Naoki Fukuda; Kazuhisa Toda; Yu Fujiwara; Xiaofei Wang; Akihiro Ohmoto; Tetsuya Urasaki; Naomi Hayashi; Yasuyoshi Sato; Kenji Nakano; Mayu Yunokawa; Makiko Ono; Junichi Tomomatsu; Hiroki Mitani; Shunji Takahashi

doi:10.21873/invivo.12113

Neutrophil-to-lymphocyte ratio as a prognostic marker for anaplastic thyroid cancer treated with lenvatinib

Naoki Fukuda, Kazuhisa Toda, Yu Fujiwara, Xiaofei Wang, Akihiro Ohmoto, Tetsuya Urasaki, Naomi Hayashi, Yasuyoshi Sato, Kenji Nakano, Mayu Yunokawa, Makiko Ono, Junichi Tomomatsu, Hiroki Mitani, Shunji Takahashi

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

Background/Aim: Lenvatinib is one of the few options for patients with anaplastic thyroid cancer (ATC). However, tumor markers for ATC treated with lenvatinib is lacking. The aim of this study was to explore whether the neutrophil-to-lymphocyte ratio (NLR) can be a tumor marker for ATC treated with lenvatinib. Patients and Methods: We retrospectively analyzed the prognostic significance of the NLR in 13 ATC patients treated with lenvatinib. Results: The disease control rate was better in patients with lower NLR (<8; 89%) than higher NLR (≥8; 25%) (p=0.05). Median progression-free survival and overall survival were longer in patients with lower NLR than higher NLR (4.0 vs. 1.6 months, p<0.05; and 10.2 vs. 3.8 months, p<0.05, respectively). Patients whose NLR on day 14 decreased compared to baseline had a slightly higher overall response rate than patients without NLR decrease (42.9% vs. 0%, p=0.19). Conclusion: The baseline NLR is a potential prognostic marker, and the change of NLR can be an early indicator of response for ATC patients treated with lenvatinib.

Original language	English
Pages (from-to)	2859-2864
Number of pages	6
Journal	In Vivo
Volume	34
Issue number	5
DOIs	https://doi.org/10.21873/invivo.12113
State	Published - Sep 2020
Externally published	Yes

Keywords

Anaplastic thyroid cancer
Lenvatinib
Neutrophil-to-lymphocyte ratio
Prognostic factors

Access to Document

10.21873/invivo.12113

Cite this

@article{3d407064d5e14a909593e568546a3500,

title = "Neutrophil-to-lymphocyte ratio as a prognostic marker for anaplastic thyroid cancer treated with lenvatinib",

abstract = "Background/Aim: Lenvatinib is one of the few options for patients with anaplastic thyroid cancer (ATC). However, tumor markers for ATC treated with lenvatinib is lacking. The aim of this study was to explore whether the neutrophil-to-lymphocyte ratio (NLR) can be a tumor marker for ATC treated with lenvatinib. Patients and Methods: We retrospectively analyzed the prognostic significance of the NLR in 13 ATC patients treated with lenvatinib. Results: The disease control rate was better in patients with lower NLR (<8; 89%) than higher NLR (≥8; 25%) (p=0.05). Median progression-free survival and overall survival were longer in patients with lower NLR than higher NLR (4.0 vs. 1.6 months, p<0.05; and 10.2 vs. 3.8 months, p<0.05, respectively). Patients whose NLR on day 14 decreased compared to baseline had a slightly higher overall response rate than patients without NLR decrease (42.9% vs. 0%, p=0.19). Conclusion: The baseline NLR is a potential prognostic marker, and the change of NLR can be an early indicator of response for ATC patients treated with lenvatinib.",

keywords = "Anaplastic thyroid cancer, Lenvatinib, Neutrophil-to-lymphocyte ratio, Prognostic factors",

author = "Naoki Fukuda and Kazuhisa Toda and Yu Fujiwara and Xiaofei Wang and Akihiro Ohmoto and Tetsuya Urasaki and Naomi Hayashi and Yasuyoshi Sato and Kenji Nakano and Mayu Yunokawa and Makiko Ono and Junichi Tomomatsu and Hiroki Mitani and Shunji Takahashi",

year = "2020",

month = sep,

doi = "10.21873/invivo.12113",

language = "English",

volume = "34",

pages = "2859--2864",

journal = "In Vivo",

issn = "0258-851X",

publisher = "International Institute of Anticancer Research",

number = "5",

}

TY - JOUR

T1 - Neutrophil-to-lymphocyte ratio as a prognostic marker for anaplastic thyroid cancer treated with lenvatinib

AU - Fukuda, Naoki

AU - Toda, Kazuhisa

AU - Fujiwara, Yu

AU - Wang, Xiaofei

AU - Ohmoto, Akihiro

AU - Urasaki, Tetsuya

AU - Hayashi, Naomi

AU - Sato, Yasuyoshi

AU - Nakano, Kenji

AU - Yunokawa, Mayu

AU - Ono, Makiko

AU - Tomomatsu, Junichi

AU - Mitani, Hiroki

AU - Takahashi, Shunji

PY - 2020/9

Y1 - 2020/9

N2 - Background/Aim: Lenvatinib is one of the few options for patients with anaplastic thyroid cancer (ATC). However, tumor markers for ATC treated with lenvatinib is lacking. The aim of this study was to explore whether the neutrophil-to-lymphocyte ratio (NLR) can be a tumor marker for ATC treated with lenvatinib. Patients and Methods: We retrospectively analyzed the prognostic significance of the NLR in 13 ATC patients treated with lenvatinib. Results: The disease control rate was better in patients with lower NLR (<8; 89%) than higher NLR (≥8; 25%) (p=0.05). Median progression-free survival and overall survival were longer in patients with lower NLR than higher NLR (4.0 vs. 1.6 months, p<0.05; and 10.2 vs. 3.8 months, p<0.05, respectively). Patients whose NLR on day 14 decreased compared to baseline had a slightly higher overall response rate than patients without NLR decrease (42.9% vs. 0%, p=0.19). Conclusion: The baseline NLR is a potential prognostic marker, and the change of NLR can be an early indicator of response for ATC patients treated with lenvatinib.

AB - Background/Aim: Lenvatinib is one of the few options for patients with anaplastic thyroid cancer (ATC). However, tumor markers for ATC treated with lenvatinib is lacking. The aim of this study was to explore whether the neutrophil-to-lymphocyte ratio (NLR) can be a tumor marker for ATC treated with lenvatinib. Patients and Methods: We retrospectively analyzed the prognostic significance of the NLR in 13 ATC patients treated with lenvatinib. Results: The disease control rate was better in patients with lower NLR (<8; 89%) than higher NLR (≥8; 25%) (p=0.05). Median progression-free survival and overall survival were longer in patients with lower NLR than higher NLR (4.0 vs. 1.6 months, p<0.05; and 10.2 vs. 3.8 months, p<0.05, respectively). Patients whose NLR on day 14 decreased compared to baseline had a slightly higher overall response rate than patients without NLR decrease (42.9% vs. 0%, p=0.19). Conclusion: The baseline NLR is a potential prognostic marker, and the change of NLR can be an early indicator of response for ATC patients treated with lenvatinib.

KW - Anaplastic thyroid cancer

KW - Lenvatinib

KW - Neutrophil-to-lymphocyte ratio

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=85090181971&partnerID=8YFLogxK

U2 - 10.21873/invivo.12113

DO - 10.21873/invivo.12113

M3 - Article

C2 - 32871825

AN - SCOPUS:85090181971

SN - 0258-851X

VL - 34

SP - 2859

EP - 2864

JO - In Vivo

JF - In Vivo

IS - 5

ER -

Neutrophil-to-lymphocyte ratio as a prognostic marker for anaplastic thyroid cancer treated with lenvatinib

Abstract

Keywords

Access to Document

Fingerprint

Cite this